Valley News - Dartmouth s Geisel medical school investigates alleged cheating vnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vnews.com Daily Mail and Mail on Sunday newspapers.
Barbara Jobst, MD, PhD. Photo by Mark Washburn
Barbara C. Jobst, MD, Dr. med, has been named the new chair of the Department of Neurology for Dartmouth-Hitchcock and Dartmouth’s Geisel School of Medicine. Previously, Jobst served as vice chair of Neurology and section chief of Adult Neurology. She has directed the Epilepsy Center at D-H and is the Louis and Ruth Frank Professor of Neuroscience at Geisel. She succeeds Jeffrey A. Cohen, MD, who retired as department chair in January 2021. Jobst is the first woman to serve as chair of Neurology at D-H and Geisel.
“I am thrilled to be chosen as the next Neurology chair as I see it as an opportunity shape and educate the next generation of neurological researchers and physicians,” Jobst said. “It will be my job to make the department even more successful than it already is, and I am excited to work with my colleagues at D-H and Geisel to achieve that goal.”
Groundwork for Covid-19 vaccine laid at Dartmouth
Geisel research being employed by Pfizer/BioNTech
January 7, 2021
Structural biologist Jason McLellan and his colleagues at Geisel and two other prominent labs conducted groundbreaking research on the coronavirus spike protein, the major surface protein that this type of virus uses to bind to human cells and invade them.
Discoveries originating in a basic science lab at Geisel School of Medicine’s Department of Biochemistry and Cell Biology are being used in the newly approved Covid-19 vaccine from the Pfizer/BioNTech partnership.
Beginning in 2016, structural biologist Jason McLellan and his colleagues at Geisel and two other prominent labs, conducted groundbreaking research on the coronavirus spike protein, the major surface protein that this type of virus uses to bind to human cells and invade them.
Discoveries originating in a basic science lab at Geisel School of Medicine’s Department of Biochemistry and Cell Biology are being used in the newly approved COVID-19 vaccine from the Pfizer/BioNTech partnership.
Beginning in 2016, structural biologist Jason McLellan, PhD, and his colleagues at Geisel and two other prominent labs, conducted groundbreaking research on the coronavirus spike protein, the major surface protein that this type of virus uses to bind to human cells and invade them.
McLellan and his team designed a special form of the spike protein that makes it more likely to be effective as a vaccine antigen, a part of the virus that can be used to stimulate antibody production in advance, and thus help the body fight off infection.